MetaVia Inc.

https://www.metaviatx.com

MetaVia Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel pharmaceuticals to address cardiometabolic diseases. Incorporated in Delaware in October 2014, the company aims to transform treatment paradigms within this therapeutic area.

The company's primary pipeline candidates include DA-1726, an oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist for the treatment of obesity, and vanoglipel (DA-1241), a G-protein-coupled receptor 119 (GPR119) agonist targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). MetaVia also maintains legacy therapeutic programs, such as ANA001, NB-01, NB-02, and Gemcabene, which address various viral, neurodegenerative, and cardiometabolic indications.

MetaVia Inc. is publicly traded on the Nasdaq Capital Market under the ticker symbol MTVA. Recent corporate activities include the dosing of the first patient in higher-dose Phase 1 studies for DA-1726 in April 2026 and the reporting of year-end 2025 financial results in March 2026. The company, led by President and CEO Hyung Heon Kim, operates as a subsidiary of Dong-A ST Co., Ltd., which holds a significant stake.

Latest updates

MetaVia Advances Dual GLP-1/Glucagon Obesity Drug Candidate into Higher-Dose Trials

Event summary

  • MetaVia initiated Part 3 of its Phase 1 clinical trial for DA-1726, a dual GLP-1/glucagon agonist for obesity.
  • The trial will evaluate one-step and two-step dose titration strategies, aiming for doses up to 64mg.
  • The study will enroll 40 obese, healthy adults and expects data in Q4 2026.
  • Preliminary data at 48mg showed 9% weight loss, waist circumference reduction, and early liver benefit.
  • DA-1726 has demonstrated improved weight loss and lipid-lowering effects compared to competitor drugs in preclinical models.

The big picture

The obesity treatment market is experiencing explosive growth, driven by the success of GLP-1 receptor agonists. MetaVia's DA-1726 aims to differentiate itself through a dual-agonist mechanism, potentially offering improved efficacy and a faster path to optimal dosing. However, the company faces significant competition and the inherent risks associated with clinical development and regulatory approval.

What we're watching

Tolerability Risk
The higher dose titration strategy carries a risk of adverse events that could derail the program, especially given the aggressive escalation schedule. Monitoring for dose-limiting toxicities will be critical.
Efficacy Threshold
While initial data is promising, DA-1726 will need to demonstrate a clear and sustained efficacy advantage over existing GLP-1 receptor agonists to justify its development costs and potential market disruption.
Commercial Adoption
The streamlined titration profile touted by MetaVia will only translate to commercial success if physicians and patients perceive it as a meaningful benefit over existing, well-established therapies.

MetaVia Posts 2025 Loss, Advances Obesity Drug DA-1726

Event summary

  • MetaVia reported a net loss of $13.0 million for the year ended December 31, 2025, compared to $27.6 million in 2024.
  • The company raised $9.3 million in a public offering in January 2026.
  • Phase 1 data for DA-1726 demonstrated 9.1% weight loss, improved glucose control, and liver benefit without titration.
  • IRB approval was received for a 16-week titration study of DA-1726, expected to begin in April 2026 with data in Q4 2026.
  • Phase 2a data for vanoglipel (DA-1241) showed improvements in glucose control, liver health, and lipidomic profiles.

The big picture

MetaVia is positioned within a rapidly evolving obesity treatment landscape dominated by GLP-1 receptor agonists. DA-1726's dual-agonist mechanism and reported benefits beyond weight loss – including improved glucose control and liver health – represent a potential competitive advantage, but require validation in later-stage trials. The company's reliance on licensing agreements, particularly with Dong-A ST, introduces a degree of dependency and potential negotiation risk.

What we're watching

Clinical Execution
The success of the upcoming Phase 1 titration study for DA-1726 will be critical in validating the initial Phase 1 data and informing dose selection for future trials, potentially impacting the drug's commercial viability.
Regulatory Pathway
The timing and outcome of MetaVia's planned end-of-Phase 2 meeting with the FDA regarding vanoglipel will significantly influence the drug's progression towards potential approval and market entry.
Financial Runway
While the recent public offering extends MetaVia's cash runway into Q4 2026, continued funding will be necessary to support ongoing clinical trials and development programs, potentially requiring further capital raises.

MetaVia Advances Obesity Drug Candidate with Dose-Escalation Trial Approval

Event summary

  • MetaVia received IRB approval to initiate Part 3 of Phase 1 clinical trials for DA-1726, a GLP-1 and glucagon dual agonist.
  • The trial will enroll 40 obese adults and evaluate one-step (48mg) and two-step (64mg) dose titration regimens over 16 weeks.
  • Previous data showed the 48mg dose produced approximately 9% weight loss and improved blood sugar control.
  • Initial dosing is expected in April 2026, with data anticipated in Q4 2026.
  • DA-1726 has demonstrated improved weight loss and lipid-lowering effects compared to competitors in preclinical models.

The big picture

The obesity treatment market is experiencing explosive growth, driven by the success of GLP-1 receptor agonists. MetaVia’s DA-1726, a dual GLP-1/glucagon agonist, aims to differentiate itself through improved efficacy and tolerability. The Phase 1 data will be critical in determining whether DA-1726 can carve out a significant share of this rapidly expanding market, which is currently dominated by Novo Nordisk and Eli Lilly.

What we're watching

Tolerability Risk
The titration strategy aims to optimize tolerability, but higher doses (64mg) introduce greater risk of adverse events that could derail development.
Competitive Landscape
The trial’s results will be closely scrutinized against existing GLP-1 therapies like semaglutide and tirzepatide, particularly regarding efficacy and side-effect profiles.
MASH Potential
How the observed liver benefit signals in earlier trials translate to efficacy in the Phase 1 titration study will be a key indicator of DA-1726's potential in the MASH market.

MetaVia Secures Patent Protection for Vanoglipel Through 2035

Event summary

  • MetaVia Inc. (MTVA) has expanded global patent protection for its GPR119 agonist, vanoglipel (DA-1241).
  • The patent portfolio includes 48 granted and pending patents across the U.S., Europe, Japan, China, and other countries.
  • The patents provide protection for vanoglipel, its manufacturing process, and potential uses in treating metabolic and liver diseases until 2035.
  • The patent portfolio was exclusively licensed from Dong-A ST Co., Ltd.

The big picture

MetaVia’s strengthened patent position for vanoglipel underscores the growing focus on GPR119 agonists as a potential therapeutic avenue for metabolic and liver diseases, a market increasingly driven by the unmet need for effective treatments for MASH. Securing this long-term protection is a critical step for MetaVia to attract investment and potentially establish a dominant position in a market estimated to reach billions of dollars in the coming decade, but it also highlights the inherent risks associated with relying on licensed technology.

What we're watching

Commercialization
The success of vanoglipel will hinge on MetaVia’s ability to navigate Phase 3 clinical trials and secure regulatory approval, given the competitive landscape in both MASH and diabetes treatment.
Dependency Risk
MetaVia’s reliance on the licensed technology from Dong-A ST Co., Ltd. creates a potential dependency risk, and future changes to the licensing agreement could impact the company’s strategy.
Patent Defense
The validity of MetaVia’s patent portfolio could be challenged, and the company’s ability to defend its intellectual property will be crucial to maintaining its market exclusivity.

MetaVia to Pitch Dual-Action Obesity Drug at Investor Forum

Event summary

  • MetaVia CEO Hyung Heon Kim will participate in a virtual investor forum on March 12, 2026.
  • The forum will focus on MetaVia’s pipeline of obesity and metabolic therapies, including DA-1726 and vanoglipel.
  • DA-1726 is a dual agonist targeting GLP1R and GCGR, showing ‘best-in-class’ potential in Phase 1 trials.
  • Vanoglipel, a GPR119 agonist, demonstrated hepatic action and glucose lowering in Phase 2a studies.

The big picture

The obesity and metabolic disease market represents a multi-billion dollar opportunity, attracting significant investment and competition. MetaVia’s focus on dual-agonist therapies positions it within a rapidly evolving space, but success hinges on demonstrating superior efficacy and navigating a complex regulatory environment. The company's ability to secure funding and partnerships will be key to advancing its pipeline and capturing market share.

What we're watching

Clinical Efficacy
The market will scrutinize whether DA-1726’s Phase 1 weight loss results can be replicated and sustained in larger, more rigorous trials, given the competitive landscape of GLP-1 agonists.
Regulatory Pathway
The FDA’s acceptance of DA-1726’s dual-agonist mechanism, and the potential for accelerated approval pathways, will heavily influence investor sentiment.
Commercialization
MetaVia’s ability to secure partnerships or demonstrate a clear commercialization strategy for vanoglipel, particularly given the crowded MASH treatment landscape, will be critical for long-term value.

MetaVia to Detail Dual-Agonist Obesity Therapy at Emerging Growth Conference

Event summary

  • MetaVia executives Hyung Heon Kim and Marshall H. Woodworth will present on February 25, 2026, at the Emerging Growth Conference.
  • The presentation will focus on MetaVia’s pipeline of obesity and metabolic therapies, including DA-1726 and vanoglipel (DA-1241).
  • DA-1726 is a novel oxyntomodulin (OXM) analogue demonstrating ‘best-in-class’ potential in Phase 1 trials.
  • Vanoglipel (DA-1241) showed direct hepatic action and glucose lowering effects in Phase 2a clinical studies.

The big picture

The obesity and metabolic disease treatment market is experiencing significant investment and innovation, driven by the increasing prevalence of these conditions and the potential for blockbuster therapies. MetaVia’s dual-agonist approach with DA-1726 represents a potential advancement over existing GLP-1 receptor agonists, but faces stiff competition from established players. The company’s success hinges on demonstrating superior efficacy and safety profiles for its therapies and navigating a complex regulatory landscape.

What we're watching

Clinical Data
The presentation's emphasis on 'best-in-class' potential for DA-1726 warrants scrutiny of the Phase 1 data; investors should assess if these results are reproducible and translate to later-stage trials.
Competitive Landscape
Given the crowded GLP-1/GCGR agonist market, MetaVia must clearly articulate DA-1726’s differentiated advantages beyond weight loss to justify its valuation and potential market share.
Regulatory Pathway
The success of vanoglipel’s direct hepatic action will be critical for regulatory approval in MASH, and the company’s strategy for demonstrating this effect in larger trials needs close monitoring.

MetaVia Secures Long-Term Patent Protection for Dual-Action Obesity Therapy

Event summary

  • MetaVia Inc. has secured a comprehensive global patent portfolio for its lead asset, DA-1726, protecting it through 2041.
  • The patent portfolio includes 39 granted and pending patents in the U.S. and internationally, exclusively licensed from Dong-A ST Co., Ltd.
  • DA-1726 is a dual GLP-1/glucagon receptor agonist designed for obesity and metabolic disorder treatment.
  • Clinical data indicates a 9% weight loss at a 48mg dose, alongside improvements in blood sugar and liver function.
  • MetaVia plans 16-week titration studies at 48mg and 64mg doses, starting in Q4 2026.

The big picture

The obesity treatment market is experiencing explosive growth, driven by rising rates of obesity and the success of GLP-1 receptor agonists. MetaVia’s DA-1726, with its dual-action mechanism, aims to capture a significant share of this market. The extensive patent protection provides a crucial barrier to entry for competitors, but the company’s success hinges on demonstrating superior efficacy and safety in later-stage trials and navigating a complex regulatory landscape.

What we're watching

Clinical Efficacy
The success of the planned titration studies at higher doses (48mg and 64mg) will be critical to demonstrating DA-1726’s efficacy and safety profile compared to existing GLP-1 treatments.
Patent Defense
The strength and defensibility of the patent portfolio against potential challenges from competitors will determine the longevity of MetaVia’s exclusivity.
Market Adoption
The speed at which physicians and patients adopt DA-1726, assuming approval, will depend on its perceived advantages over existing therapies and its reimbursement landscape.

MetaVia's AI Collaboration Validates Vanoglipel's Broad Therapeutic Potential

Event summary

  • MetaVia is collaborating with Syntekabio, utilizing their DeepMatcher® AI platform to model vanoglipel (DA-1241).
  • AI analysis identified inflammatory diseases, cardiometabolic disorders, and cancer as key therapeutic targets for vanoglipel.
  • Phase 2a clinical trial data showed vanoglipel demonstrated direct hepatic activity and improvements in glucose metabolism in 109 patients.
  • Syntekabio is a KOSDAQ-listed company (226330) offering AI-driven drug discovery services.

The big picture

The collaboration highlights the growing trend of integrating AI into drug discovery, accelerating target identification and potentially reducing development costs. MetaVia's focus on cardiometabolic diseases represents a significant market opportunity, but the expansion into cancer, while promising, introduces new risks and complexities. The validation of AI-driven target identification will be closely watched by other biopharma companies seeking to leverage similar technologies.

What we're watching

Clinical Validation
The success of vanoglipel will hinge on replicating the Phase 2a results in larger, more diverse patient populations, particularly given the AI-predicted expansion into cancer indications.
AI Dependency
MetaVia's increasing reliance on Syntekabio's AI platform introduces a potential vendor risk and could impact development timelines if the partnership encounters issues.
Regulatory Pathway
The identification of cancer as a potential target will likely necessitate a more complex and protracted regulatory pathway for vanoglipel, potentially delaying market entry.

MetaVia Secures $9.3 Million Offering, Bolsters Obesity Drug Development

Event summary

  • MetaVia Inc. closed a $9.3 million underwritten public offering of Class A and Class B Units.
  • The offering included the full exercise of the underwriter’s over-allotment option, comprising 3,005,574 shares and associated warrants.
  • The offering was priced at $3.10 per share, accompanied by Series C and Series D warrants.
  • The warrants, if fully exercised, could generate an additional $28.0 million in gross proceeds.
  • Proceeds will primarily fund the clinical development of DA-1726, a novel obesity treatment.

The big picture

This offering provides MetaVia with a crucial capital infusion at a time when biotech companies face increasing scrutiny and higher financing costs. The inclusion of warrants, while offering potential upside, also introduces complexity and potential dilution risk. The success of DA-1726, a dual GLP1R/GCGR agonist, is key to MetaVia's long-term value proposition in the competitive obesity treatment market, where existing GLP-1 agonists dominate.

What we're watching

Clinical Milestones
The timing and results of the Phase 1b Part III clinical trial for DA-1726 will be critical, as a positive readout triggers the callability of a significant tranche of warrants, potentially diluting existing shareholders.
Financial Runway
Given the ongoing clinical development costs, MetaVia’s ability to extend its financial runway beyond the current proceeds will depend on continued investor interest and potential partnerships.
Warrant Dynamics
The exercise or non-exercise of the outstanding warrants will significantly impact MetaVia’s capital structure and future financing needs, creating potential dilution or upside for investors.

MetaVia's DA-1726 Phase 1 Data Show Promise in Metabolic Disease

Event summary

  • MetaVia's DA-1726 demonstrated a 9.8 cm (3.8 inch) statistically significant reduction in waist circumference at Day 54 in a Phase 1b trial.
  • The trial showed a 23.7% reduction in liver stiffness (VCTE) by Day 54, suggesting a direct hepatic effect.
  • Patients experienced a 9.1% (21.2 lbs) average weight loss and a 12.3 mg/dL reduction in fasted glucose by Day 54.
  • The trial, extended to 8 weeks at 48mg, reported no treatment-related discontinuations and mild to moderate gastrointestinal events.

The big picture

The obesity treatment market is experiencing rapid growth driven by the success of GLP-1 receptor agonists, but a significant unmet need remains for therapies that address both weight loss and metabolic dysfunction, particularly non-alcoholic steatohepatitis (MASH). MetaVia's DA-1726, with its dual GLP-1/glucagon receptor agonist mechanism, aims to capture a larger share of this market by offering a more comprehensive solution, but faces competition from established players and emerging dual agonists.

What we're watching

Titration Risk
The success of the planned 16-week titration studies, moving to 64mg, will be critical to demonstrating improved tolerability and a competitive advantage over existing GLP-1 therapies.
Reimbursement
The company's assertion that DA-1726's glucose-lowering profile without elevations could lead to broader insurance coverage will need to be validated through clinical and economic data.
Hepatic Impact
The observed reduction in liver stiffness warrants further investigation to determine if DA-1726 can meaningfully impact MASH progression and become a dual treatment option.

MetaVia Stakes Claim at Key MASH-TAG Conference Amidst GLP-1 Competition

Event summary

  • MetaVia Inc. will sponsor and participate in the 10th Annual MASH-TAG 2026 Conference, January 8-10 in Park City, Utah.
  • The company is developing DA-1726 (obesity treatment) and vanoglipel (DA-1241, MASH treatment).
  • DA-1726 is an oxyntomodulin (OXM) analogue acting as a GLP1R/GCGR dual agonist, showing promising Phase 1 results.
  • Vanoglipel is a GPR119 agonist demonstrating direct hepatic action in Phase 2a trials.

The big picture

MetaVia's sponsorship of MASH-TAG underscores the company's focus on the rapidly evolving cardiometabolic disease treatment space, particularly in obesity and MASH. The company faces significant competition from established players with GLP-1 receptor agonists, necessitating a clear differentiation strategy for DA-1726. Success hinges on demonstrating superior efficacy and safety profiles for both DA-1726 and vanoglipel in later-stage clinical trials.

What we're watching

Competitive Landscape
The conference participation signals MetaVia's intent to highlight DA-1726's differentiation against increasingly crowded GLP-1 market, and the success of this messaging will be critical for investor perception.
Clinical Progress
Whether MetaVia can maintain the 'best-in-class' narrative for DA-1726 will depend on upcoming Phase 2 and 3 trial data, particularly concerning efficacy and safety compared to existing GLP-1 therapies.
Commercial Strategy
The level of engagement and messaging around vanoglipel at MASH-TAG will indicate MetaVia’s commitment to the MASH indication and its potential commercialization pathway, given the competitive landscape in NASH.
CID: 13